Yes, Alzheimer’s disease and Lewy body dementia do occur together—and they occur far more frequently than many people realize. The presence of both neuropathological features in the same brain is not a rare exception but a common occurrence. Research shows that approximately 30 to 60% of patients with Alzheimer’s disease pathology also have Lewy body pathology, meaning the abnormal alpha-synuclein protein associated with Lewy body disease is present in their brain tissue. This combination, sometimes called mixed dementia when both conditions contribute significantly to cognitive decline, changes how the disease progresses, how symptoms appear, and how treatment decisions get made.
For decades, Alzheimer’s disease and Lewy body dementia were conceptualized as distinct conditions—separate diagnoses with separate mechanisms. But autopsy data and modern neuropathological research have revealed a more complex reality. A rigorous autopsy series examining 95 cases that met strict diagnostic criteria for Alzheimer’s disease found that 56.8% of these brains also contained Lewy bodies. The reverse is equally striking: among people clinically diagnosed with dementia with Lewy bodies, between 48 and 91% show concurrent Alzheimer’s disease neuropathological changes when their brains are examined after death, with most studies confirming comorbidity rates above 50%. This overlap has major implications for how families experience the disease, how clinicians should approach diagnosis, and which treatments might help.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Common Is the Coexistence of Both Diseases?
- What Is Mixed Dementia Neuropathology?
- How Does Mixed Pathology Affect Cognitive Symptoms?
- Detecting Mixed Pathology in Living Patients
- Treatment Challenges When Both Pathologies Are Present
- Genetic and Molecular Links Between the Two Diseases
- What Mixed Pathology Means for Prognosis and Family Planning
How Common Is the Coexistence of Both Diseases?
The frequency of mixed Alzheimer’s and Lewy body pathology becomes clear when you look at large-scale autopsy data across different populations. In a consecutive autopsy series of community subjects—people who died from various causes, not just those clinically diagnosed with dementia—Lewy body pathology was found in 10.3% of non-demented subjects and 31.2% of demented subjects. In most of these demented individuals with Lewy bodies, Alzheimer’s pathology was also present. This suggests that by the time someone reaches late life, the likelihood of having pathological evidence of multiple dementia-related conditions increases substantially. The prevalence data shows a clear pattern: having one form of dementia pathology significantly increases the odds of having the other. This is not because the diseases cause each other in a simple way, but rather because they share certain risk factors and may stem from overlapping biological vulnerabilities.
A person with early-stage Lewy body pathology may develop Alzheimer’s pathology years later, or vice versa. The timeline and sequence matter for prognosis, but the ultimate outcome is that both sets of protein abnormalities accumulate in the same brain. What makes this finding clinically important is that it challenges the traditional diagnostic approach. When a neurologist or geriatrician makes a diagnosis of “Alzheimer’s disease” or “Lewy body dementia” based on clinical symptoms and cognitive testing alone, they are making an educated guess about which pathology is primary. They cannot be certain whether a second pathology is also present without neuropathological examination after death. This diagnostic uncertainty has real consequences for predicting disease trajectory and selecting treatments.
What Is Mixed Dementia Neuropathology?
Mixed dementia refers to the concurrent presence of multiple distinct neuropathological changes in the brain. In the context of Alzheimer’s and lewy body disease, this means the presence of both amyloid-beta plaques and tau tangles (the hallmarks of Alzheimer’s) alongside Lewy bodies (abnormal alpha-synuclein deposits) in the same brain tissue. These are not the same pathology manifesting differently; they are genuinely different proteins accumulating in abnormal forms. The brain regions affected can vary, with Lewy bodies often most prominent in the substantia nigra, limbic regions, and neocortex, while Alzheimer’s pathology tends to follow a predictable progression from entorhinal cortex outward to broader cortical areas. The neuropathological definition of this combination has been formalized by international diagnostic consensus.
When both Alzheimer’s pathology (meeting specified criteria for Braak stage and amyloid burden) and Lewy body pathology (meeting defined thresholds for alpha-synuclein distribution) are present, the case is classified as having mixed pathology. However, severity matters: a small number of incidental Lewy bodies in someone whose brain is dominated by Alzheimer’s pathology may have minimal clinical relevance, while extensive Lewy body pathology coinciding with advanced Alzheimer’s changes will likely alter the clinical picture substantially. One important limitation to remember is that autopsy-confirmed diagnosis remains the gold standard for determining what pathology was actually present during life. While living individuals can now be tested with emerging biomarkers, the full neuropathological picture—including the regional distribution and severity of each type of pathology—can only be determined after death. This means that clinical diagnoses made during life, even by experienced specialists, represent a best judgment rather than a confirmed fact. For someone experiencing progressive cognitive decline, the actual neuropathological substrate may be more complex than the clinical diagnosis suggests.
How Does Mixed Pathology Affect Cognitive Symptoms?
When both Alzheimer’s and Lewy body pathology are present, the pattern of cognitive and behavioral symptoms can differ from cases where only one pathology is dominant. Alzheimer’s disease typically presents with progressive memory loss as an early and prominent feature. Lewy body dementia often features visual hallucinations, parkinsonian movement symptoms, and fluctuating cognition as its signature elements. When both are present, patients may experience a more complex symptom profile that doesn’t fit neatly into either category. Research indicates that mixed pathology is associated with accelerated cognitive decline compared to either condition alone. This means that individuals with both Alzheimer’s and Lewy body pathology may lose cognitive abilities more rapidly than someone whose pathology is limited to one disease.
The precise mechanism remains under investigation, but the combined burden of two distinct pathological processes appears to exert a more aggressive effect on the brain’s functioning than either pathology in isolation. Some individuals with mixed pathology develop cognitive impairment at a younger age and progress more quickly toward severe dementia. The specific cognitive domains affected may also differ in mixed pathology cases. Someone with pure Alzheimer’s might show prominent memory deficits with relatively preserved executive function in early stages, while someone with pure Lewy body dementia might show earlier executive and visuospatial problems with memory preserved. A person with both pathologies may show deficits across multiple domains simultaneously, creating diagnostic ambiguity and making it harder for families to understand what is happening. For example, a patient might show both the memory loss typical of Alzheimer’s and the visual hallucinations and attention fluctuations typical of Lewy body disease, presenting an overlapping clinical picture.
Detecting Mixed Pathology in Living Patients
For most of the history of dementia diagnosis, detecting mixed pathology required autopsy. A person would be clinically diagnosed during life, and only after death would neuropathological examination confirm whether the suspected diagnosis was accurate and whether additional pathology was present. This limitation meant that families and clinicians had to manage disease without certainty about the actual underlying cause. Recent advances in biomarker technology are beginning to change this picture. The most promising development is the alpha-synuclein seed amplification assay (SAA), a test performed on cerebrospinal fluid that can detect Lewy body pathology with remarkable specificity. In cerebrospinal fluid from individuals with a clinical diagnosis of Alzheimer’s dementia, the alpha-synuclein SAA is 97% specific for detecting actual Lewy body pathology. This means that if the test is positive, there is a very high likelihood that Lewy body pathology is truly present.
In large cohorts of cognitively impaired individuals, cerebrospinal fluid biomarkers detect the coexistence of Alzheimer’s and Lewy body pathology in approximately 20 to 25% of cases, independent of the primary clinical diagnosis. This capability to diagnose mixed dementia in living patients opens the door to more informed prognosis discussions and potentially more targeted treatment approaches. However, these biomarker tests come with practical limitations. Cerebrospinal fluid testing requires a lumbar puncture, an invasive procedure that some patients cannot or will not undergo. The tests are not yet universally available outside research centers, and insurance coverage remains variable. Additionally, the presence of biomarker evidence of a pathology does not automatically tell clinicians how much that pathology is contributing to the person’s current symptoms—a person might have asymptomatic or presymptomatic Lewy body pathology detected by biomarkers while their cognitive symptoms are primarily driven by Alzheimer’s pathology. The clinical significance of the biomarker finding must be interpreted in context.
Treatment Challenges When Both Pathologies Are Present
Currently approved treatments for Alzheimer’s disease, such as certain monoclonal antibodies targeting amyloid-beta, have been shown to slow cognitive decline in early Alzheimer’s disease. However, their effect in patients with mixed Alzheimer’s and Lewy body pathology is not as well established. Someone with both pathologies might receive an Alzheimer’s-directed treatment, but that treatment may only address part of the underlying problem if Lewy body pathology is also substantially contributing to decline. The presence of Lewy body pathology can also increase the risk of certain adverse effects; for instance, patients with Lewy body disease are known to have heightened sensitivity to antipsychotic medications, which can cause severe reactions. This creates a clinical dilemma for treatment decisions. A neurologist caring for someone with suspected mixed dementia must weigh whether Alzheimer’s-specific treatments are appropriate, what doses might be safe given potential Lewy body involvement, and whether there are any Lewy body-specific interventions that might also help.
Currently, there are no approved medications specifically targeting Lewy body pathology or mixed dementia. Clinicians must often make treatment choices based on which pathology is thought to be primary, while acknowledging uncertainty about the actual neuropathological substrate. This uncertainty is an important limitation of current clinical practice. Behavioral and psychological symptoms, common in both conditions, may require careful medication management. Many psychiatric medications can worsen Lewy body symptoms or are contraindicated, narrowing the treatment options available. Non-pharmacological interventions—structured cognitive activities, physical therapy, music therapy, and behavioral approaches—may be particularly important in mixed dementia, as they can potentially benefit from addressing multiple domains of function without the medication risks that accompany pharmacological options.
Genetic and Molecular Links Between the Two Diseases
Recent genetic research has revealed surprising connections between Alzheimer’s disease and Lewy body dementia at the molecular level, suggesting they may share some common biological pathways despite their different hallmark pathologies. The National Institute on Aging has published findings from genetic studies indicating ties between Lewy body dementia and Alzheimer’s disease, as well as links between Lewy body dementia and Parkinson’s disease. These genetic connections suggest that certain genetic variants that increase Alzheimer’s risk might also influence the likelihood or severity of Lewy body pathology, or vice versa.
This shared genetic architecture provides one explanation for why mixed pathology is so common. Individuals with genetic predispositions to develop one type of pathology may also be at higher risk for developing the other, either because they share genetic risk factors or because the presence of one pathology alters brain biology in a way that facilitates the other. Understanding these genetic links has implications for family risk counseling and for identifying individuals at highest risk for developing mixed dementia.
What Mixed Pathology Means for Prognosis and Family Planning
Families facing a dementia diagnosis need to understand that prognosis depends partly on which pathology is present and how severe it is. In general, mixed dementia tends toward a more severe and faster progression than either condition alone, but individual variation is substantial. Some people with mixed pathology progress relatively slowly, while others decline more rapidly. The presence of Lewy body pathology alongside Alzheimer’s generally means a less predictable disease course, with greater likelihood of fluctuating symptoms and behavioral challenges.
For practical planning purposes, families should understand that a clinical diagnosis of “Alzheimer’s disease” or “Lewy body dementia” may not capture the full neuropathological picture. This is particularly relevant when considering long-term care planning, medication decisions, and setting realistic expectations with the care team. If biomarker testing reveals evidence of mixed pathology, that information can inform more nuanced discussions about what to expect. The accelerated cognitive decline associated with mixed pathology suggests that families should plan for progression that may occur faster than typical Alzheimer’s disease alone, while remaining alert to the fluctuations and behavioral symptoms more characteristic of Lewy body disease.
- —
